Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
Would you re-challenge a CLL patient, who had good response to Zanubrutinib but contracted cryptococcal pneumonia, with another BTK inhibitor?
Infections are part of the natural history of CLL. While cryptococcal meningitis is the uncommon one in CLL, it does occur when these patients are on steroids, have prior receipt of fludarabine, bendamustine, or other treatments which suppress the cellular immune system (in particular CD4+ T-cells)....
Would you re-challenge a CLL patient, who had good response to Zanubrutinib but contracted cryptococcal pneumonia, with another BTK inhibitor?
Infections are part of the natural history of CLL. While cryptococcal meningitis is the uncommon one in CLL, it does occur when these patients are on steroids, have prior receipt of fludarabine, bendamustine, or other treatments which suppress the cellular immune system (in particular CD4+ T-cells)....
For patients who meet criteria to be treated with 3 months of CAPEOX based on IDEA study, is it reasonable to use capecitabine alone for 3 months and drop oxaliplatin during the COVID pandemic?
This is indeed a question for our times. There are no data to support three months of capecitabine. In fact, the studies that suggest the single agent fluoropyrimidine carries more of the benefit than oxaliplatin are all based on six-month trials. While single agent capecitabine may be necessary if...
How would you manage a well differentiated neuroendocrine cancer without a known primary that is not clearly resectable but not overtly metastatic?
NENs of unknown primary are relatively rare, and they constitute less than 5% of all CUPs. Previous series review showed that NENs with an unknown primary site account for 10-14% of all NENs. Most of them present with liver mets, and a majority of these represent gastroenteropancreatic NETs. Clinica...
What parasites do you screen for in your workup of HES?
In my practice, if GI symptoms (particularly diarrhea), then culture for stool ova and parasites (broad screen). If there are no GI symptoms, then only screening for Strongyloides with a blood test for Strongyloides antibody. If there is a recent travel history or a patient immigrated from areas wi...
How do you manage Cancer-Associated Retinopathy (CAR) in a patient who doesn’t have a known cancer diagnosis, given the difficulty in finding the underlying cancer and the risks of using immunosuppressive treatments to preserve vision?
Auto-immune retinopathy, whether paraneoplastic or non-paraneoplastic, can be a very difficult condition to diagnose and manage. There are a few features that raise suspicion for a paraneoplastic cause particularly, such as rapid progression and more significant intraocular inflammation (anterior ch...
How would you manage a gastric MALT patient with anemia and peri-gastric and abdominal retrocaval nodal involvement?
Of course, I would first want to know if the disease was H. pylori+. Studies have shown that involved perigastric lymph nodes and deep invasion of the gastric wall are associated with a lower chance of achieving a complete response with triple therapy, but in most patients with gastric MALT (a very ...
For ER+ breast cancers that are clinical Stage IIB (T2N1) nearing locally advanced stages, what criteria do you use to determine if you would offer neoadjuvant chemotherapy?
This is an interesting question. Assuming this is regarding ER positive but HER2 negative tumors, the factors I would consider that would favor the decision to use upfront chemotherapy are the following: 1. Tumors that are grade 3 or high Ki-67 2. Low ER positive tumors 3. Younger, premenopausal wom...
Would you recommend adjuvant chemotherapy therapy to a premenopausal patient with ER+ lobular breast cancer who had a partial response to neoadjuvant endocrine therapy?
One approach is if you have enough tissue from the diagnostic core biopsy to run an Oncotype then base your decision on adjuvant chemo from that. This is assuming you are confident she is a N1 case (no treatment effects noted in other nodes). There is an ASCO 2018 abstract from Mayo (Talal Hilal et ...
What is your approach to localized pancreatic cancer that would otherwise be resectable, except for poor patient characteristics?
Tough question—since there is no prospectively validated phase III data to guide us in such situations, we've adopted an approach that utilizes bi-modality treatment sequencing, punctuated with aggressive supportive care and frequent multidisciplinary evaluation (q 2 months) to re-assess eligibility...